A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

(1)

Seite 1 von 3 - Literaturverzeichnis zum Titelthema „Neues aus der Pneumologie“

Literaturverzeichnis zum Titelthema „Neues aus der Pneumologie“

Bayerisches Ärzteblatt 10/2010, Seite 506 ff

Dr. Sonja Beckh, Dr. Manfred Wagner und Professor Dr. Joachim H. Ficker

1. National Emphysema Treatment Trial Research Group. A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073

2. Aljuri N, Freitag L.Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783

3. Fessler, H. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol 106: 755-756, 2009

4. Mantri, S., et al., Measurement of Collateral Flow in the Lung with a Dedicated

Endobronchial Catheter System. J Bonchol Intervent Pulmonol, 2009. 16(2): p.141-144

5. Hopkinson NS, Toma TP, Hansell DM et al. Effect of bronchoscopic lung volume

reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005; 171: 453-460

6. Wood DE, McKenna RJ Jr, Yusen RD et al. A multicenter trial of an intrabronchial valve for treatment of sever emphysema. J Thorac Cardiovasc Surg 2007; 133: 65-73

7. Herth FJF, Schmidt B, Ficker JH et al. Germany pilot safety and feasibility study of bronchoscopic thermal vapor ablation (BTVA) for lung volume reduction in patients with heterogeneous emphysema with upper lobe predominance. Eur Respir J 2009; 35: A 1827

8. Eberhardt R, Schmidt B, Wagner M, Gompelmann D, Ficker JH, Herth FJF. Deutsche Pilotstudie zur Lungenvolumenreduktion mittels Thermoablation (BTVA) bei Patienten mit heterogenem, oberlappenbetontem Lungenemphysem. Pneumologie 2010, 64: S 245

9. Cooper CB, Celli B. Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches, COPD: Journal of Chronic Obstructive Pulmonary Disease 2008,5:6,376 - 381

10. Faul JL, Sievert H, Percutaneous Creation of Arteriovenous Shunts. Vascular Disease Management, 2008; 5: 128-133

11. Jerrentrup A, Wagner M, Ficker JH, Steier J, Teschler H, Blass H, Pfeifer M Vogelmeier C für die ROX-Study Group. Erste Erfahrungen mit einer therapeutischen peripheren AV-Fistel bei Patienten mit hochgradiger COPD. Pneumologie 2010; 64: S252

12. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:

1543 - 1554

13. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948 – 955

14. Beier J, Chanez P, Martinot J-B, Schreurs AJM, Tkáčová, Bao W, Jack D, Higgins M.

Safety, tolerability and efficacy of indacateraol, a novel once-daily ß₂–agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulmonary Pharmacology & Therapeutics 2007; 20: 740 – 749

(2)

15. Buhl R, Pieters W, Jack D, Owen R, Kramer B, Higgins M. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am J Respir Crit Care Med 2009; 179: A6185

16. Beeh KM, Beier J. The short, the long and the ”ultra.long“: Why duration of

bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010 Apr 19

17. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacateraol 150f once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med 2010;10:11 18. LaForce C, Korenblat P, Osborne P et al. 24-hour bronchodilator efficacy of single

doses of indacateraol in patients with persistent asthma : comparison woth placebo and formoterol. Curr Med Res Opn 2009; 25: 2353-2359

19. Calverley PMA, Rabe KF, Goehring U-M et al. for the M2-124 M2-125 study groups.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694

20. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL et al. For the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet 2009;

374: 695-703

21. Nationale Versorgungsleitlinie Asthma 2009, Kurzfassung, 2. Auflage, März 2010, http://www.versorgungsleitlinien.de

22. Ukena D, Fishman L, Niebling WB. Asthma bronchiale – Diagnostik und Therapie im Erwachsenenalter. Dtsch Arztebl 2008; 105: A 385 – 94

23. Höffken G, Lorenz J, Kern W, Welte T, Bauer T,, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H. S 3 Leitlinie zu Epidemiologie, Diagnostik, antimikrobieller Therapie und Management von

erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009. Teil 1: Pneumologie 2009; 63: 549 – 577; Teil 2: Pneumologie 2009; 63: 613 – 652

24. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms.

Interdisziplinäre S3 –Leitlinie der Deutschen Gesellschaft für Pneumologie und

Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010; 64: S 23 – S 155

25. Kohlhäufl M. TNM-Klassifikation 2010. Was ist neu? Pneumo-News 2010 (2):10-11

26. Wagner M, Ficker JH (Hrsg.). Autofluoreszenz-Bronchoskopie: Grundlagen und klinische Anwendung. Bremen: Uni-Med, 2007

27. Lee P, Brokx HAP, Postmus PE, Sudetja TG, Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions Lung Cancer 2007; 58; 44-49 28. Sheski FD, Mathur PN. Endobronchial ultrasound. Chest 2008; 133: 264 – 270

29. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008;

133:887-891

30. Gomez M, Silvestri GA. Endobronchial ultrasound for the diagnosis and staging of lung cancer. Proc Am Thorac Soc 2009; 6: 180 – 186

(3)

31. Scagliotti GV, Parikh P, Pawel J von et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–3551

32. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550

33. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967

34. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. Proc Am Soc Clin Oncol 2009; 27: Abstract 8001

35. Brückl WM, Wiest GH, und Ficker JH. Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC… Pneumologie 2010 in press

36. ESC/ERS - Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; doi:10.1093/eurheartj/ehp 297

37. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78 – 84

38. Galié N, Rubin LJ, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371: 2093-2100

39. Mc Laughlin VM, Archer SA, Badesch DB, et al. ACCF/AHA clinical expert consensus document on pulmonary hypertension : a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2009: 53:

1573-1619